Differences in cardiovascular event rates between atorvastatin and simvastatin among new users: managed-care experience

By Willke Richard J.   Zhou Steve   Vogel Robert A.  

Current Medical Research and Opinion, Vol. 24, Iss. 10, 2008-10 ,pp. : 2873-2882

Informa Healthcare

Access to resources Recommend Favorite

Cardiovascular event rates in atorvastatin patients versus patients switching from atorvastatin to simvastatin

By Jacobson Terry A.  

Current Medical Research and Opinion, Vol. 29, Iss. 7, 2013-07 ,pp. : 773-781

Informa Healthcare

Access to resources Recommend Favorite

Economic impacts attributable to the early clinical benefit of atorvastatin therapy – a US managed care perspective

By Straka Robert J.   Mamdani Muhammad   Damen Joep   Kuntze C. Erik E.   Liu Larry Z.   Botteman Marc F.   Koren Michael J.  

Current Medical Research and Opinion, Vol. 23, Iss. 7, 2007-07 ,pp. : 1517-1529

Informa Healthcare

Access to resources Recommend Favorite

Tuberculosis screening prior to anti‐tumor necrosis factor therapy among patients with immune‐mediated inflammatory diseases in Japan: a longitudinal study using a large‐scale health insurance claims database

By  

INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (ELECTRONIC), Vol. 20, Iss. 11, 2017-11 ,pp. : 1674-1683

John Wiley & Sons Inc

Access to resources Recommend Favorite

Budget impact of rosuvastatin initiation in high-risk hyperlipidemic patients from a US managed care perspective

By Montouchet C.  

Journal of Medical Economics, Vol. 16, Iss. 7, 2013-07 ,pp. : 907-916

Informa Healthcare

Access to resources Recommend Favorite